Strategic question
Which OMICS-led ventures tackling oncology and wellness are mature enough to partner with an enterprise insurer?
How Galen Growth helped
From market signal to decision-ready evidence
Leveraging HealthTech Alpha, we ran structured ecosystem mapping across five priority markets, evaluated 528 ventures against client criteria, and co-developed a prioritised shortlist matched to oncology and wellness use cases.
Outcomes
Provided a defensible, comparative view of the OMICS venture landscape, separating mature, insurer-ready partners from experimental plays.
Decision enabled: Enabled the carrier to confidently prioritise partnership conversations with a short, decision-ready venture list.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Sourcing HealthTech Ventures to Power Non-Fluid Underwriting
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
Pressure-Testing a Digital Health Partnership Before Commitment
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?
Helping an APAC Insurer Prioritise Markets, Categories and Venture Targets
Which APAC markets, therapeutic areas and Digital Health categories should we prioritise to accelerate regional growth?